ERBB2 and invasive breast carcinoma: Similarly, Tabuchi and colleagues demonstrate that healthy controls have a significantly higher titer of autoantibodies against human epidermal growth factor receptor 2 (HER2) compared to patients with invasive breast carcinoma [33].